Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

1990-11

AUTHORS

R. P. Castleberry, A. H. Ragab, C. P. Steuber, B. Kamen, S. Toledano, K. Starling, D. Norris, P. Burger, J. P. Krischer

ABSTRACT

To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various non-central nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses. More... »

PAGES

401-406

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/bf00198601

DOI

http://dx.doi.org/10.1007/bf00198601

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1017171155

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/2084075


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1109", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Neurosciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aziridines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzoquinones", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Brain Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Child, Preschool", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Administration Schedule", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Evaluation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drugs, Investigational", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasm Recurrence, Local", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Neoplasms", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "University of Alabama at Birmingham", 
          "id": "https://www.grid.ac/institutes/grid.265892.2", 
          "name": [
            "The Departments of Pediatrics of the University of Alabama at Birmingham, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Castleberry", 
        "givenName": "R. P.", 
        "id": "sg:person.0626116531.27", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626116531.27"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Emory University", 
          "id": "https://www.grid.ac/institutes/grid.189967.8", 
          "name": [
            "Emory University, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ragab", 
        "givenName": "A. H.", 
        "id": "sg:person.010643352004.84", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010643352004.84"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Baylor University", 
          "id": "https://www.grid.ac/institutes/grid.252890.4", 
          "name": [
            "Baylor University, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Steuber", 
        "givenName": "C. P.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "The University of Texas Southwestern Medical Center", 
          "id": "https://www.grid.ac/institutes/grid.267313.2", 
          "name": [
            "University of Texas Southwestern Medical School, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kamen", 
        "givenName": "B.", 
        "id": "sg:person.0616713135.35", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616713135.35"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Miami", 
          "id": "https://www.grid.ac/institutes/grid.26790.3a", 
          "name": [
            "University of Miami, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Toledano", 
        "givenName": "S.", 
        "id": "sg:person.01242012473.51", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242012473.51"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "West Virginia University", 
          "id": "https://www.grid.ac/institutes/grid.268154.c", 
          "name": [
            "West Virginia University, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Starling", 
        "givenName": "K.", 
        "id": "sg:person.065570553.31", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065570553.31"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "The Cleveland Clinics, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Norris", 
        "givenName": "D.", 
        "id": "sg:person.01141744115.25", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141744115.25"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Duke University Hospital", 
          "id": "https://www.grid.ac/institutes/grid.189509.c", 
          "name": [
            "Duke University Medical Center, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Burger", 
        "givenName": "P.", 
        "id": "sg:person.0653131115.45", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653131115.45"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "University of Florida", 
          "id": "https://www.grid.ac/institutes/grid.15276.37", 
          "name": [
            "The University of Florida and member institutions of The Pediatric Oncology Group, St. Louis, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Krischer", 
        "givenName": "J. P.", 
        "id": "sg:person.015434510637.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015434510637.88"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/bf00165153", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002279955", 
          "https://doi.org/10.1007/bf00165153"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00165185", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002576749", 
          "https://doi.org/10.1007/bf00165185"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00180194", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1009528930", 
          "https://doi.org/10.1007/bf00180194"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/0277-5379(84)90193-7", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1012921883"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031779669"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00148387", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041519111", 
          "https://doi.org/10.1007/bf00148387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00148387", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041519111", 
          "https://doi.org/10.1007/bf00148387"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00153636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045673869", 
          "https://doi.org/10.1007/bf00153636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/bf00153636", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045673869", 
          "https://doi.org/10.1007/bf00153636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.1987.5.3.464", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1079514700"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1079995803", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1080114927", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081779436", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081874945", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1081908006", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1082281986", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "1990-11", 
    "datePublishedReg": "1990-11-01", 
    "description": "To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various non-central nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/bf00198601", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isFundedItemOf": [
      {
        "id": "sg:grant.2693162", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693295", 
        "type": "MonetaryGrant"
      }, 
      {
        "id": "sg:grant.2693270", 
        "type": "MonetaryGrant"
      }
    ], 
    "isPartOf": [
      {
        "id": "sg:journal.1094201", 
        "issn": [
          "0167-6997", 
          "1573-0646"
        ], 
        "name": "Investigational New Drugs", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "4", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "8"
      }
    ], 
    "name": "Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors", 
    "pagination": "401-406", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "51cf607a92c430b57f26f5fc6a457aaa25027bd012fb2000825f0f7c54c6a306"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "2084075"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8309330"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/bf00198601"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1017171155"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/bf00198601", 
      "https://app.dimensions.ai/details/publication/pub.1017171155"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:49", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000371_0000000371/records_130794_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/BF00198601"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/bf00198601'


 

This table displays all metadata directly associated to this object as RDF triples.

250 TRIPLES      21 PREDICATES      57 URIs      35 LITERALS      23 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/bf00198601 schema:about N09a8ef2bbcc2433d9f1b22dbf29e1d93
2 N0d02e49d217d413ab4f695e8d608bb30
3 N142826fb366f4f74a9c7e24673cf0e40
4 N1d229df77ab347acbdaeffcd24aebd1e
5 N2775568fae764d13a3053ccfc32163ee
6 N31bd9049ea354ef38dc709845369c57b
7 N338c138d0a114180acc8213c4d97e729
8 N59e77d0504d04ee6b41ffc82c457a99f
9 N7a9eef41a71f4f8eb88ccba19d46eea4
10 N8081a20939e249c99971675f1b126009
11 Nafce477d72e14e87ab701b862df69f6f
12 Nb85300489cf342ff882bd3366a61035f
13 Ned6cdedb865f4d65811e677e6180caef
14 Nf3ed4c26e99a4fb296899d78f5bb658b
15 anzsrc-for:11
16 anzsrc-for:1109
17 schema:author Nbb94790698a24499859f6049331e1000
18 schema:citation sg:pub.10.1007/bf00148387
19 sg:pub.10.1007/bf00153636
20 sg:pub.10.1007/bf00165153
21 sg:pub.10.1007/bf00165185
22 sg:pub.10.1007/bf00180194
23 https://app.dimensions.ai/details/publication/pub.1079995803
24 https://app.dimensions.ai/details/publication/pub.1080114927
25 https://app.dimensions.ai/details/publication/pub.1081779436
26 https://app.dimensions.ai/details/publication/pub.1081874945
27 https://app.dimensions.ai/details/publication/pub.1081908006
28 https://app.dimensions.ai/details/publication/pub.1082281986
29 https://doi.org/10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v
30 https://doi.org/10.1016/0277-5379(84)90193-7
31 https://doi.org/10.1200/jco.1987.5.3.464
32 schema:datePublished 1990-11
33 schema:datePublishedReg 1990-11-01
34 schema:description To assess the response rates and toxicity of AZQ in children with recurrent brain and other malignant solid tumors, a phase II study was implemented by the Pediatric Oncology Group. Eligible patients received AZQ 18 mg/M2/week i.v. for 4 doses followed by a 2 week rest period. Each dose was given over four hours (1/3 over the initial 20 minutes). After the first year, the dosage was reduced to 13 mg/M2 due to myelotoxicity resulting in treatment delays. No objective responses were observed in 73 evaluable children with various non-central nervous system tumors. Of the 91 patients with brain tumors, there were 4 CR's and 2 PR's in patients with astrocytoma, ependymoma, glioblastoma multiforme, oligodendroglioma, brain stem glioma and intracranial yolk sac tumor (median duration, 10 months; range, 2-20+ months). Three of 4 CR's were achieved with a dosage of 18 mg/M2/week. An additional 13 children with brain tumors experienced stable or improved disease (duration, 2-36 + months; median 7.5 months). The principal toxicity was myelosuppression which was cumulative but there were also 3 allergic reactions to AZQ. We conclude that for selected brain tumors, the rates of objective response and stable disease plus the duration of responses support further assessment of AZQ in combination with other agents. Furthermore, the 18 mg/M2 dosage may provide better responses.
35 schema:genre research_article
36 schema:inLanguage en
37 schema:isAccessibleForFree false
38 schema:isPartOf N62449f3f0de0435b8281192dc9326681
39 N8e5d066abe8a47ddbfab9aa81ca12f48
40 sg:journal.1094201
41 schema:name Aziridinylbenzoquinone (AZQ) in the treatment of recurrent pediatric brain and other malignant solid tumors
42 schema:pagination 401-406
43 schema:productId N12d6d5b9e86d483cba3fe4ac27b39228
44 N506404193b30445b96f69ca121208810
45 N5bda6dae38084c9fbed5fc9503fd10f5
46 Ne8ed497304354820a7b5eabbea69ddf1
47 Nebbbb2c1e7a344bba9bcf5c7c0c26cba
48 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017171155
49 https://doi.org/10.1007/bf00198601
50 schema:sdDatePublished 2019-04-11T13:49
51 schema:sdLicense https://scigraph.springernature.com/explorer/license/
52 schema:sdPublisher N87f4c708c7594df09cce95ca8e67b506
53 schema:url http://link.springer.com/10.1007/BF00198601
54 sgo:license sg:explorer/license/
55 sgo:sdDataset articles
56 rdf:type schema:ScholarlyArticle
57 N09a8ef2bbcc2433d9f1b22dbf29e1d93 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
58 schema:name Adolescent
59 rdf:type schema:DefinedTerm
60 N0d02e49d217d413ab4f695e8d608bb30 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
61 schema:name Drug Evaluation
62 rdf:type schema:DefinedTerm
63 N12d6d5b9e86d483cba3fe4ac27b39228 schema:name dimensions_id
64 schema:value pub.1017171155
65 rdf:type schema:PropertyValue
66 N142826fb366f4f74a9c7e24673cf0e40 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Child
68 rdf:type schema:DefinedTerm
69 N1d229df77ab347acbdaeffcd24aebd1e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
70 schema:name Brain Neoplasms
71 rdf:type schema:DefinedTerm
72 N26f24afb62194701a6b65a6d32e7a8a0 rdf:first sg:person.015434510637.88
73 rdf:rest rdf:nil
74 N2775568fae764d13a3053ccfc32163ee schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
75 schema:name Adult
76 rdf:type schema:DefinedTerm
77 N2a6a9af68c194b76ab70db2d4fc3ab01 rdf:first sg:person.010643352004.84
78 rdf:rest Naae88928dc504145872b7fa38de6760e
79 N31bd9049ea354ef38dc709845369c57b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Neoplasms
81 rdf:type schema:DefinedTerm
82 N338c138d0a114180acc8213c4d97e729 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Antineoplastic Agents
84 rdf:type schema:DefinedTerm
85 N36ef053e79af44179693b221ce74724a rdf:first sg:person.065570553.31
86 rdf:rest Ne8edf3e0fd5942738eaf170760281cc1
87 N3c66938943f74a08a90fc2e88d785f03 rdf:first sg:person.0616713135.35
88 rdf:rest Nfcfb7693d14a477ba131706e610ce525
89 N506404193b30445b96f69ca121208810 schema:name doi
90 schema:value 10.1007/bf00198601
91 rdf:type schema:PropertyValue
92 N55bb0098f0d4485ca9e29638095e237d rdf:first sg:person.0653131115.45
93 rdf:rest N26f24afb62194701a6b65a6d32e7a8a0
94 N59e77d0504d04ee6b41ffc82c457a99f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
95 schema:name Neoplasm Recurrence, Local
96 rdf:type schema:DefinedTerm
97 N5bda6dae38084c9fbed5fc9503fd10f5 schema:name pubmed_id
98 schema:value 2084075
99 rdf:type schema:PropertyValue
100 N62449f3f0de0435b8281192dc9326681 schema:issueNumber 4
101 rdf:type schema:PublicationIssue
102 N7a9eef41a71f4f8eb88ccba19d46eea4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
103 schema:name Benzoquinones
104 rdf:type schema:DefinedTerm
105 N8081a20939e249c99971675f1b126009 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
106 schema:name Humans
107 rdf:type schema:DefinedTerm
108 N87f4c708c7594df09cce95ca8e67b506 schema:name Springer Nature - SN SciGraph project
109 rdf:type schema:Organization
110 N8e5d066abe8a47ddbfab9aa81ca12f48 schema:volumeNumber 8
111 rdf:type schema:PublicationVolume
112 Naae88928dc504145872b7fa38de6760e rdf:first Ncdb26dc9cf3f465e8552e5cef57765a2
113 rdf:rest N3c66938943f74a08a90fc2e88d785f03
114 Nafce477d72e14e87ab701b862df69f6f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
115 schema:name Drugs, Investigational
116 rdf:type schema:DefinedTerm
117 Nb85300489cf342ff882bd3366a61035f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
118 schema:name Child, Preschool
119 rdf:type schema:DefinedTerm
120 Nbb94790698a24499859f6049331e1000 rdf:first sg:person.0626116531.27
121 rdf:rest N2a6a9af68c194b76ab70db2d4fc3ab01
122 Ncdb26dc9cf3f465e8552e5cef57765a2 schema:affiliation https://www.grid.ac/institutes/grid.252890.4
123 schema:familyName Steuber
124 schema:givenName C. P.
125 rdf:type schema:Person
126 Nd94b8267620749fe873e406094633600 schema:name The Cleveland Clinics, USA
127 rdf:type schema:Organization
128 Ne8ed497304354820a7b5eabbea69ddf1 schema:name readcube_id
129 schema:value 51cf607a92c430b57f26f5fc6a457aaa25027bd012fb2000825f0f7c54c6a306
130 rdf:type schema:PropertyValue
131 Ne8edf3e0fd5942738eaf170760281cc1 rdf:first sg:person.01141744115.25
132 rdf:rest N55bb0098f0d4485ca9e29638095e237d
133 Nebbbb2c1e7a344bba9bcf5c7c0c26cba schema:name nlm_unique_id
134 schema:value 8309330
135 rdf:type schema:PropertyValue
136 Ned6cdedb865f4d65811e677e6180caef schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
137 schema:name Drug Administration Schedule
138 rdf:type schema:DefinedTerm
139 Nf3ed4c26e99a4fb296899d78f5bb658b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
140 schema:name Aziridines
141 rdf:type schema:DefinedTerm
142 Nfcfb7693d14a477ba131706e610ce525 rdf:first sg:person.01242012473.51
143 rdf:rest N36ef053e79af44179693b221ce74724a
144 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
145 schema:name Medical and Health Sciences
146 rdf:type schema:DefinedTerm
147 anzsrc-for:1109 schema:inDefinedTermSet anzsrc-for:
148 schema:name Neurosciences
149 rdf:type schema:DefinedTerm
150 sg:grant.2693162 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00198601
151 rdf:type schema:MonetaryGrant
152 sg:grant.2693270 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00198601
153 rdf:type schema:MonetaryGrant
154 sg:grant.2693295 http://pending.schema.org/fundedItem sg:pub.10.1007/bf00198601
155 rdf:type schema:MonetaryGrant
156 sg:journal.1094201 schema:issn 0167-6997
157 1573-0646
158 schema:name Investigational New Drugs
159 rdf:type schema:Periodical
160 sg:person.010643352004.84 schema:affiliation https://www.grid.ac/institutes/grid.189967.8
161 schema:familyName Ragab
162 schema:givenName A. H.
163 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010643352004.84
164 rdf:type schema:Person
165 sg:person.01141744115.25 schema:affiliation Nd94b8267620749fe873e406094633600
166 schema:familyName Norris
167 schema:givenName D.
168 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01141744115.25
169 rdf:type schema:Person
170 sg:person.01242012473.51 schema:affiliation https://www.grid.ac/institutes/grid.26790.3a
171 schema:familyName Toledano
172 schema:givenName S.
173 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01242012473.51
174 rdf:type schema:Person
175 sg:person.015434510637.88 schema:affiliation https://www.grid.ac/institutes/grid.15276.37
176 schema:familyName Krischer
177 schema:givenName J. P.
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015434510637.88
179 rdf:type schema:Person
180 sg:person.0616713135.35 schema:affiliation https://www.grid.ac/institutes/grid.267313.2
181 schema:familyName Kamen
182 schema:givenName B.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0616713135.35
184 rdf:type schema:Person
185 sg:person.0626116531.27 schema:affiliation https://www.grid.ac/institutes/grid.265892.2
186 schema:familyName Castleberry
187 schema:givenName R. P.
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0626116531.27
189 rdf:type schema:Person
190 sg:person.0653131115.45 schema:affiliation https://www.grid.ac/institutes/grid.189509.c
191 schema:familyName Burger
192 schema:givenName P.
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0653131115.45
194 rdf:type schema:Person
195 sg:person.065570553.31 schema:affiliation https://www.grid.ac/institutes/grid.268154.c
196 schema:familyName Starling
197 schema:givenName K.
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.065570553.31
199 rdf:type schema:Person
200 sg:pub.10.1007/bf00148387 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041519111
201 https://doi.org/10.1007/bf00148387
202 rdf:type schema:CreativeWork
203 sg:pub.10.1007/bf00153636 schema:sameAs https://app.dimensions.ai/details/publication/pub.1045673869
204 https://doi.org/10.1007/bf00153636
205 rdf:type schema:CreativeWork
206 sg:pub.10.1007/bf00165153 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002279955
207 https://doi.org/10.1007/bf00165153
208 rdf:type schema:CreativeWork
209 sg:pub.10.1007/bf00165185 schema:sameAs https://app.dimensions.ai/details/publication/pub.1002576749
210 https://doi.org/10.1007/bf00165185
211 rdf:type schema:CreativeWork
212 sg:pub.10.1007/bf00180194 schema:sameAs https://app.dimensions.ai/details/publication/pub.1009528930
213 https://doi.org/10.1007/bf00180194
214 rdf:type schema:CreativeWork
215 https://app.dimensions.ai/details/publication/pub.1079995803 schema:CreativeWork
216 https://app.dimensions.ai/details/publication/pub.1080114927 schema:CreativeWork
217 https://app.dimensions.ai/details/publication/pub.1081779436 schema:CreativeWork
218 https://app.dimensions.ai/details/publication/pub.1081874945 schema:CreativeWork
219 https://app.dimensions.ai/details/publication/pub.1081908006 schema:CreativeWork
220 https://app.dimensions.ai/details/publication/pub.1082281986 schema:CreativeWork
221 https://doi.org/10.1002/1097-0142(19850915)56:6<1311::aid-cncr2820560615>3.0.co;2-v schema:sameAs https://app.dimensions.ai/details/publication/pub.1031779669
222 rdf:type schema:CreativeWork
223 https://doi.org/10.1016/0277-5379(84)90193-7 schema:sameAs https://app.dimensions.ai/details/publication/pub.1012921883
224 rdf:type schema:CreativeWork
225 https://doi.org/10.1200/jco.1987.5.3.464 schema:sameAs https://app.dimensions.ai/details/publication/pub.1079514700
226 rdf:type schema:CreativeWork
227 https://www.grid.ac/institutes/grid.15276.37 schema:alternateName University of Florida
228 schema:name The University of Florida and member institutions of The Pediatric Oncology Group, St. Louis, USA
229 rdf:type schema:Organization
230 https://www.grid.ac/institutes/grid.189509.c schema:alternateName Duke University Hospital
231 schema:name Duke University Medical Center, USA
232 rdf:type schema:Organization
233 https://www.grid.ac/institutes/grid.189967.8 schema:alternateName Emory University
234 schema:name Emory University, USA
235 rdf:type schema:Organization
236 https://www.grid.ac/institutes/grid.252890.4 schema:alternateName Baylor University
237 schema:name Baylor University, USA
238 rdf:type schema:Organization
239 https://www.grid.ac/institutes/grid.265892.2 schema:alternateName University of Alabama at Birmingham
240 schema:name The Departments of Pediatrics of the University of Alabama at Birmingham, USA
241 rdf:type schema:Organization
242 https://www.grid.ac/institutes/grid.267313.2 schema:alternateName The University of Texas Southwestern Medical Center
243 schema:name University of Texas Southwestern Medical School, USA
244 rdf:type schema:Organization
245 https://www.grid.ac/institutes/grid.26790.3a schema:alternateName University of Miami
246 schema:name University of Miami, USA
247 rdf:type schema:Organization
248 https://www.grid.ac/institutes/grid.268154.c schema:alternateName West Virginia University
249 schema:name West Virginia University, USA
250 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...